Open an account

ADC Therapeutics SA

ADCT · NYSE

$1.52+$0.08 (+5.56%)TodayMarket closed ·
Prev close $1.44

About ADCT

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. The company is headquartered in Epalinges, Vaud and currently employs 188 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.

Employees
188
Headquarters
Epalinges, Vaud
Listed
May 15, 2020
Sector
Health Care
Industry
Biotechnology
Website
adctherapeutics.com

ADCT key statistics

Market cap
194.05M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.76M
Volume
1.06M
Open price
$1.45
High today
$1.55
Low today
$1.43
52 Week high
$4.98
52 Week low
$0.7796

ADC Therapeutics SA (ADCT) at a glance

As of Oct 20, 2026, ADC Therapeutics SA (ADCT) shares are priced at $1.52, giving the company a market cap of 194.05M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.43 and $1.55. The current price is 6.3% above the day's low and 1.9% below its high.

Volume so far is 1.06M shares, below the average of 1.76M shares a day.

Over the past year ADC Therapeutics SA has ranged from $0.7796 to $4.98, and now sits 18% of the way up that range.

ADC Therapeutics SA met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported -$0.09 per share against an estimate of -$0.2162.

The average analyst price target is $2.68, 76.2% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

33%of 3 analyst ratings say Buy
  • Buy33.3%
  • Hold66.7%
  • Sell0.0%
Price target · 6 analystsAvg $2.68
Low
$0.505
Now
$1.52
High
$5.25

ADCT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 38.3% on average.

  1. Q3 FY24: reported -$0.42 per share against an estimate of -$0.4029
  2. Q4 FY24: reported -$0.29 per share against an estimate of -$0.4199
  3. Q1 FY25: reported -$0.36 per share against an estimate of -$0.4114
  4. Q2 FY25: reported -$0.38 per share against an estimate of -$0.4835
  5. Q3 FY25: reported -$0.30 per share against an estimate of -$0.3689
  6. Q4 FY25: reported -$0.04 per share against an estimate of -$0.2737
  7. Q1 FY26: reported -$0.13 per share against an estimate of -$0.2193
  8. Q2 FY26: reported -$0.09 per share against an estimate of -$0.2162

ADCT news

  • Press releasePRNewswire

    ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements

  • Press releasePRNewswire

    ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

  • Press releasePRNewswire

    ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

  • Press releasePRNewswire

    ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

  • Piero Cingari

    These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

  • Press releasePRNewswire

    ADC Therapeutics Announces New Employee Inducement Grant

  • Press releasePRNewswire

    ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial

  • Press releasePRNewswire

    ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.